
Opinion|Videos|August 14, 2024
True Prevalence of Hypercortisolism
The panel of medical experts discuss the prevalence of hypercortisolism based on the CATALYST trial.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What were the key findings from Part 1: Prevalence phase of the CATALYST study?
- How does the data from the CATALYST trial change the narrative about the true prevalence of hypercortisolism in diabetes?
- How does this prevalence data fit with the growing body of evidence regarding autonomous adrenal cortisol secretion?
- How would you respond to clinicians that reference “false positives” or “pseudo cushings” as an explanation to these findings?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Long-Term Tegoprubart Data in Kidney Transplantation, With Andrew Adams
2
Q&A: Which Factors Guide the Choice Between JAKi, Biologics, or Other AD Drugs?
3
GLP-1 Receptor Agonists Reshape CKD Treatment Sequencing, With Pranav Garimella, MD
4
Furoscix ReadyFlow (Furosemide) and its Impact on HF, CKD Edema Treatment
5










































































